Genetically Modified Pig Kidney Sustains Man for Record 271 Days Without Dialysis

Surgeons implanted the organ from a GalSafe pig after knocking out three immunogenic genes and adding seven human transgenes to regulate complement, coagulation, and inflammation. The recipient, previously on dialysis, maintained stable creatinine and required no filtration support until month nine, when chronic rejection prompted explantation ahead of a successful human transplant. This case extends prior xenografts that failed within two months and demonstrates that multi-gene editing can overcome hyperacute and acute humoral barriers in a living patient.

Organ shortage kills roughly 17 Americans daily awaiting kidneys. Xenotransplantation directly targets that gap by creating an on-demand supply, but success hinges on consistent long-term graft survival rather than short-term proof-of-concept. The nine-month window here reveals both progress and the remaining hurdle: controlling adaptive immunity and chronic vasculopathy without lifelong heavy immunosuppression that itself raises infection and cancer risks.

Next steps include expanded FDA-cleared trials at multiple centers using kidneys from pigs with additional edits targeting NK-cell and macrophage responses. If one-year graft survival exceeds 60 percent in the first 50 patients, regulators are expected to consider accelerated approval pathways by 2027.